Cerevel Therapeutics Holdings, Inc.
CERE
Classifica tra le azioni
#2803
Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical firm... Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing treatments for a range of neuroscience disorders. The company boasts a robust pipeline of therapeutic candidates currently undergoing various phases of clinical evaluation. Key assets include emraclidine, a positive allosteric modulator (PAM) in Phase 1b trials for schizophrenia. Another PAM, Darigabat, is being assessed in a Phase 2 proof-of-concept study for drug-resistant focal onset seizures in epilepsy, as well as in a Phase 1 trial for acute anxiety. For Parkinson's disease, Cerevel is advancing Tavapadon, a selective dopamine D1/D5 partial agonist, through Phase 3 clinical trials for both early and late stages of the condition. A related compound, CVL-871, also a selective dopamine D1/D5 partial agonist, is in Phase 2a trials for dementia-related apathy. The company's portfolio further includes CVL-936, a selective dopamine D3-preferring antagonist in Phase I for substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist targeting major depressive disorder and substance use disorder; and CVL-047, a selective PDE4 inhibitor also aimed at major depressive disorder and substance use disorder. Beyond individual compounds, Cerevel is actively developing an M4 agonist program for psychosis and related indications, alongside an LRRK2 inhibitor program designed to address the progression of Parkinson's disease. Founded in 2018, Cerevel Therapeutics is headquartered in Cambridge, Massachusetts.
Prezzo delle azioni
$44.96
Ultima sincronizzazione: 2024-08-01
Capitalizzazione di mercato
$6.67B
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
US
Scambia Cerevel Therapeutics Holdings, Inc. (CERE)
Categoria
Healthcare
Numero di azioni in circolazione per Cerevel Therapeutics Holdings, Inc. (CERE)
Numero di azioni in circolazione al March 2024: 181.61M
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Cerevel Therapeutics Holdings, Inc., il numero attuale di azioni in circolazione è 181.61M. Alla fine del December 2022, la società aveva 151.27M azioni in circolazione. Il numero di azioni in circolazione è solitamente influenzato da split azionari e riacquisti.
Storico delle azioni in circolazione di Cerevel Therapeutics Holdings, Inc. (CERE) dal 2012 al 2026
Azioni in circolazione alla fine di ogni anno
| Anno | Azioni in circolazione | Cambia |
|---|---|---|
| 2026 (TTM) | 181.61M | 12.07% |
| 2023 | 162.06M | 7.13% |
| 2022 | 151.27M | 10.76% |
| 2021 | 136.58M | 15.57% |
| 2020 | 118.18M | -7.04% |
| 2019 | 127.12M | 79.86% |
| 2018 | 70.68M | 396.40% |
| 2015 | 14.24M | 0.00% |
| 2014 | 14.24M | 0.00% |
| 2013 | 14.24M | 0.00% |
| 2012 | 14.24M | 0.00% |
Azioni in circolazione per aziende simili o concorrenti
| Azienda | Azioni in circolazione | Differenza | Il paese |
|---|---|---|---|
| 253.90M | 39.80% |
US
|
|
| 396.00M | 118.05% |
US
|
|
| 478.91M | 163.70% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -65.76% |
NL
|
